Neochem Bio Solutions Ltd
Incorporated in 2006, Neochem Bio Solutions Ltd. is engaged in the business of manufacturing of specialty performance chemicals.[1]
- Market Cap ₹ 182 Cr.
- Current Price ₹ 106
- High / Low ₹ 121 / 63.0
- Stock P/E 12.0
- Book Value ₹ 50.6
- Dividend Yield 0.00 %
- ROCE 28.1 %
- ROE 25.4 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 28.8%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 161 days.
- Working capital days have increased from 77.8 days to 164 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of Nifty SME Emerge
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| 49 | 48 | 61 | 84 | 111 | 134 | |
| Sales growth | -1% | +27% | +38% | +32% | +44% | |
| 45 | 44 | 55 | 71 | 91 | 110 | |
| Operating Profit | 4 | 4 | 6 | 13 | 20 | 23 |
| OPM % | 7% | 9% | 10% | 15% | 18% | 17% |
| 0 | 1 | 1 | 2 | 2 | 1 | |
| Interest | 1 | 2 | 3 | 4 | 4 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 2 | 3 | 10 | 17 | 20 |
| Tax % | 25% | 28% | 31% | 25% | 30% | |
| 1 | 1 | 2 | 7 | 12 | 15 | |
| EPS in Rs | 1.87 | 1.20 | 1.65 | 6.36 | 7.03 | 8.60 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 32% |
| TTM: | 44% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 122% |
| TTM: | 37% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 29% |
| Last Year: | 25% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 3 | 5 | 7 | 7 | 17 | 17 |
| Reserves | 1 | 3 | 6 | 13 | 62 | 70 |
| 23 | 26 | 33 | 36 | 18 | 33 | |
| 19 | 16 | 18 | 24 | 20 | 29 | |
| Total Liabilities | 46 | 51 | 63 | 79 | 117 | 149 |
| 12 | 15 | 19 | 19 | 20 | 31 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 3 |
| Investments | 0 | 0 | 0 | 0 | 6 | 5 |
| 34 | 36 | 45 | 60 | 91 | 110 | |
| Total Assets | 46 | 51 | 63 | 79 | 117 | 149 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -1 | -1 | -1 | 2 | -17 | |
| -3 | -3 | 12 | -1 | -9 | |
| 4 | 4 | -11 | -1 | 26 | |
| Net Cash Flow | 0 | -0 | 0 | -0 | 0 |
| Free Cash Flow | -4 | -4 | 11 | 1 | -19 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -36% | -23% | -10% | 23% | -70% |
Ratios
Standalone / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 102 | 107 | 100 | 110 | 161 |
| Inventory Days | 141 | 173 | 172 | 157 | 143 |
| Days Payable | 186 | 155 | 142 | 111 | 56 |
| Cash Conversion Cycle | 58 | 125 | 131 | 156 | 247 |
| Working Capital Days | 17 | 19 | 30 | 39 | 164 |
| ROCE % | 12% | 14% | 26% | 28% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Capacity Utilization % |
|
|||
| Domestic Customer Count count |
||||
| Esters & Bio-based Segment Revenue Share % |
||||
| Home & Personal Care (HPC) Industry Revenue Share % |
||||
| Production Volume MT |
||||
| Textile Industry Revenue Share % |
||||
| R&D Expenditure (Percentage of Turnover) % |
||||
Extracted by Screener AI
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
- H1 FY2027 earnings call transcript posted; revenue up 50%, PAT up 43%, cyber fraud Rs1.47 crore disclosed.
-
Analysts/Institutional Investor Meet/Con. Call Updates
- Audio recording of investor/analyst conference call held on 29 October 2026 shared online.
-
Investor Presentation
- Submitted H1 FY27 investor presentation; revenue ₹68.9 crore, EBITDA ₹12.4 crore, PAT ₹7.8 crore.
-
Outcome of Board Meeting
- Board approved H1 FY2026 results and appointed new CFO and CCO effective 27 October 2026.
-
Analysts/Institutional Investor Meet/Con. Call Updates
- H1 FY27 earnings conference call scheduled for 29 October 2026 at 2:00 PM after 27 October board meeting.
Concalls
-
Nov 2026Transcript PPT REC
-
Sep 2026PPT
-
Jul 2026PPT
-
May 2026Transcript PPT
-
Mar 2026PPT
Business Profile:[1]
Operates as a specialty performance chemical company with 350+ customized formulations across four primary product segments, ''Polymers, Surfactants, Silicones
and esters /bio-based sustainable solutions''.
It has 50+ pan‑India authorized distributors, serving
225+ domestic customers, with customer presence
in 12 countries, 22,000 MTPA ISO‑certified capacity
in Ahmedabad, 40 registered trademarks, an in‑house
R&D lab, and a Zero Liquid Discharge facility.[2]